Ultragenyx Pharmaceutical Inc, a biopharma company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare genetic diseases, and Mereo BioPharma Group plc - ...

Mereo BioPharma Group plc (NASDAQ: MREO) and Ultragenyx Pharmaceutical (NASDAQ: RARE) Inc. announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 ...

Mereo BioPharma Group (NASDAQ:MPH) and Ultragenyx Pharmaceutical (NASDAQ:RARE) today announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) ...

Patients are expected to continue dosing in the ongoing Phase 3 Orbit and Cosmic clinical studies. Final analyses will be conducted after patients have been on therapy for at least 18 months.

Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 Orbit study and Phase 3 Cosmic study.

Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 Orbit study and Phase 3 Cosmic study.

Data from Orbit and Cosmic studies expected around the end of the yearNOVATO, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc ...